Neumora faces April 2027 Nasdaq compliance deadline

A closing bid of at least $1.00 for 10 consecutive business days is required, and additional time depends on Nasdaq Capital Market eligibility.

Available on EDGAR 10/30/2026 - 04:05 PM EDT Accepted by SEC EDGAR 10/30/2026 - 04:05 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Neumora Therapeutics, Inc. (NMRA) received notice from Nasdaq that it does not meet the $1.00 minimum bid price requirement for continued listing on The Nasdaq Global Select Market. The company has until April 26, 2027 to regain compliance by having its closing bid price meet or exceed $1.00 per share for at least 10 consecutive business days during the 180-calendar-day compliance period.

If it does not meet the requirement by that date, Neumora may be eligible for additional time if it applies to transfer to The Nasdaq Capital Market and meets specified listing requirements. If compliance is not regained within the applicable periods, Nasdaq may notify the company that its common stock is subject to delisting; the company would be entitled to appeal. Neumora is considering options, including a reverse stock split, and says there is no assurance it will regain compliance.

0 points · 0 major

NegativeiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 1 point

How the balance works

Positive

• None.

Negative

• Moderate pointThe $1.00 minimum bid-price deficiency has a compliance deadline of April 26, 2027.

Filing Explained

The filing reports a reverse split only as an option under consideration, not as a completed action; if effected, it would reduce the share count and proportionally raise the per-share price, while leaving company value unchanged by the split itself.

8-K Event Classification

Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

1 item

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities

The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.

Key Figures

Minimum bid price: $1.00 per share Compliance period: 180 calendar days Compliance deadline: April 26, 2027 +1 more

4 metrics

Minimum bid price $1.00 per share Nasdaq continued listing requirement

Compliance period 180 calendar days Period to regain compliance after Nasdaq's notice

Compliance deadline April 26, 2027 Deadline stated in the notice

Required consecutive business days 10 consecutive business days Closing bid price must meet or exceed $1.00 per share

Key Terms

minimum bid price requirement, continued listing requirement for market value of publicly held shares, reverse stock split

3 terms

minimum bid price requirement regulatory

"not in compliance with the $1.00 minimum bid price requirement"

A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.

continued listing requirement for market value of publicly held shares regulatory

"continued listing requirement for market value of publicly held shares"

reverse stock split technical

"including effecting a reverse stock split of its common stock"

A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why did NMRA receive a Nasdaq listing notice?

Nasdaq notified Neumora that its common stock does not meet the $1.00 minimum bid price requirement for continued listing on The Nasdaq Global Select Market.

When does NMRA have to regain Nasdaq bid-price compliance?

Neumora has until April 26, 2027 to regain compliance. The closing bid price must meet or exceed $1.00 per share for a minimum of 10 consecutive business days during the 180-calendar-day period.

Can NMRA get more time to meet Nasdaq's bid-price requirement?

Neumora may be eligible for additional time if it applies to transfer to The Nasdaq Capital Market, meets the continued listing requirement for market value of publicly held shares and the other initial listing standards except the minimum bid price requirement, pays an application fee, and notifies Nasdaq of its intent to cure the deficiency.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false 0001885522 0001885522 2026-10-26 2026-10-26

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 26, 2026

Neumora Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-41802		84-4367680
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

260 Arsenal Place, Suite 1
Watertown, Massachusetts		02472
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (857) 760-0900

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		NMRA		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On October 26, 2026, Neumora Therapeutics, Inc. (the “Company”) received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Global Select Market, as set forth in Listing Rule 5450(a)(1). In accordance with Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until April 26, 2027, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company’s common stock must meet or exceed $1.00 per share for a minimum of ten consecutive business days during this 180-day period.

If the Company is not in compliance by April 26, 2027, the Company may be eligible for additional time to regain compliance. To qualify, the Company would be required to submit an application to transfer to The Nasdaq Capital Market, which would require the Company to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, except for the minimum bid price requirement. In addition, the Company would be required to pay an application fee to Nasdaq and notify Nasdaq of its intent to cure the minimum bid price deficiency.

If the Company does not regain compliance within the allotted compliance periods, including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Company’s common stock will be subject to delisting. The Company would then be entitled to appeal Nasdaq’s determination, but there can be no assurance that Nasdaq would grant the Company’s request for continued listing.

The Company intends to monitor the closing bid price of its common stock and consider options to resolve the noncompliance with the minimum bid price requirement, including effecting a reverse stock split of its common stock. There can be no assurance that the Company will be able to regain compliance with the minimum bid price requirement or will otherwise be in compliance with other Nasdaq listing criteria.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						NEUMORA THERAPEUTICS, INC.
Date: October 30, 2026				By:		/s/ Michael Milligan
						Michael Milligan Chief Financial Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.1 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 17.6 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 11.0 KB